| Chlamydia trachomatis |
| Mycoplasma genitalium |
| Mycoplasma hominis |
| Neisseria gonorrhoeae |
| Trichomonas vaginalis |
| Ureaplasma urealyticum |
| Ureaplasma parvum |
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Sexually transmitted infections (STIs) represent a significant global health burden. In recent years, the issue has gained increased attention due to the rapidly rising rates of infection and the emergence of antibiotic-resistant strains, particularly in Neisseria gonorrhoeae and Mycoplasma genitalium. Accurate and timely diagnosis is essential for selecting appropriate treatment options, reducing transmission rates, and preventing long-term complications associated with untreated infections.
Nucleic acid amplification tests (NAATs) have emerged as highly sensitive and specific diagnostic methods for the detection of STIs. These technologies include polymerase chain reaction (PCR), transcription-mediated amplification (TMA), and strand displacement assays. Multiplex real-time PCR (RT-PCR) platforms offer the advantage of simultaneously detecting multiple pathogens within a single reaction, enabling comprehensive syndromic testing for a panel of targets.
Solaris Diagnostics Laboratory utilizes an advanced multiplex PCR platform that detects the following pathogens as part of its comprehensive STI profile:
The assay is based on quantitative PCR methodology ensuring high sensitivity, specificity, and efficient multiplex detection. This approach supports rapid, accurate diagnosis and facilitates appropriate clinical management of sexually transmitted infections.
References
Bodiybadu K, Danielewski J, Plummer E, Bradshaw CS, Machalek DA, Garland SM, Vodstrcil LA, Murray GL. Comparison of Seegene AnyPlexTM II STI-7e with standard-of-care diagnostic methods for the detection of Mycoplasma genitalium, Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. Lett Appl Microbiol. 2023 Jan 23;76(1):ovac002. doi: 10.1093/lambio/ovac002. PMID: 36688743.
Tao G, Patel CG, Stanford KA. Low sexually transmitted infection (STI) screening and presumptive treatment and high STI positivity among United States females visiting the emergency department after sexual assault. Acad Emerg Med. 2025 Mar;32(3):292-299. doi: 10.1111/acem.15058. Epub 2024 Dec 3. PMID: 39627651.
Statement on Medical Necessity
All ordered tests should be medically necessary for the diagnosis or detection of disease, illness, impairment, symptom, syndrome, or disorder and the results should be used in the medical management and treatment decisions for the patient. Solaris requires ICD-10 codes with each order for lab testing and both the tests ordered and the diagnosis should be documented in the provider’s medical record for the patient. The United States Department of Health and Human Services, Office of Inspector General, takes the position that a provider who orders medically unnecessary tests may be subject to civil penalties.
Panels and Profiles
Solaris offers Providers the convenience of ordering test combinations in a group at times with the flexibility to choose appropriate test(s) for individual patients. Providers should only order those tests that he or she believes are medically necessary for each patient, and a lesser inclusive profile or individual tests should be ordered if not all tests in the test combination/profile are medically necessary. All tests offered in a test combination/profile may be ordered separately as individual tests. Solaris encourages clients to contact their Solaris representative if the testing configurations shown do not meet individual needs for any reason, or if some other combination of procedures is needed.
CPT Codes
CPT Codes listed are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are the responsibility of the billing party and are listed here for informational purposes. Correct coding may vary from one carrier to another. Solaris may bill specific carriers using codes other than what is shown.
For questions or inquiries related to testing please reach out to
customerservice@solarisdx.com or contact us by phone at (844) 550-0308.
Contact Information
Helpful Links
